Participants and treatment
Comorbidity
A total of 291 participants were enrolled in the primary trial from August 2012 to April 2015, with 156 assigned to CBT-I and 135 to the SET group. Of the enrolled participants, a total of 231 (119 CBT-I; 112 SET) provided blood specimens at baseline plus at least one of two subsequent follow up visits to ascertain our primary outcome, p16CONSORT flow diagramBaseline sample characteristics by treatment groupComorbidity score is derived from the Charlson Comorbidity Index [Treatment adherence and acceptability did not differ between treatment arms, as reported previously [